Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

BACKGROUND: More than 2.7 million hospitalizations of COVID-19-infected patients have occurred in Europe alone since the outbreak of the coronavirus in 2020. Interventions against SARS-CoV-2 are still in high need to prevent admissions to ICUs worldwide. FX06, a naturally occurring peptide in humans...

Descripción completa

Detalles Bibliográficos
Autores principales: Kloka, Jan, Friedrichson, Benjamin, Dauth, Stephanie, Foldenauer, Ann Christina, Bulczak-Schadendorf, Anita, Vehreschild, Maria J. G. T., Matos, Francisco Maio, Riera-Mestre, Antoni, van Asselt, Antoinette D. I., De Robertis, Edoardo, Juskeviciene, Vilma Traskaite, Meybohm, Patrick, Tomescu, Dana, Lacombe, Karine, Stehouwer, Coen D. A., Zacharowski, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389510/
https://www.ncbi.nlm.nih.gov/pubmed/35986390
http://dx.doi.org/10.1186/s13063-022-06609-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389510/
https://www.ncbi.nlm.nih.gov/pubmed/35986390
http://dx.doi.org/10.1186/s13063-022-06609-x

Ejemplares similares